BIOSMART CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,985 KRW | +10.65% |
|
-6.47% | +45.55% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 75,016 | 86,858 | 155,503 | 109,620 | 63,929 | 69,894 |
| Enterprise Value (EV) 1 | 92,840 | 83,281 | 175,870 | 167,960 | 127,227 | 127,269 |
| P/E ratio | 25.4 x | 3.93 x | -17.9 x | 78.7 x | 88.6 x | 6.15 x |
| Yield | - | 1.45% | - | - | - | - |
| Capitalization / Revenue | 0.64 x | 0.55 x | 0.93 x | 0.58 x | 0.16 x | 0.15 x |
| EV / Revenue | 0.79 x | 0.52 x | 1.06 x | 0.89 x | 0.32 x | 0.28 x |
| EV / EBITDA | 7.63 x | 10.9 x | 45.7 x | 12.4 x | 6.74 x | 6.97 x |
| EV / FCF | -8.14 x | -50 x | -13.3 x | -11.5 x | 14.1 x | 633 x |
| FCF Yield | -12.3% | -2% | -7.54% | -8.69% | 7.1% | 0.16% |
| Price to Book | 0.93 x | 0.82 x | 1.61 x | 1.11 x | 0.66 x | 0.62 x |
| Nbr of stocks (in thousands) | 19,978 | 20,013 | 19,198 | 19,198 | 19,198 | 20,407 |
| Reference price 2 | 3,755 | 4,340 | 8,100 | 5,710 | 3,330 | 3,425 |
| Announcement Date | 3/18/19 | 3/13/20 | 3/19/21 | 3/23/22 | 3/21/23 | 3/19/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 117,733 | 158,968 | 166,429 | 189,183 | 391,822 | 456,164 |
| EBITDA 1 | 12,174 | 7,653 | 3,846 | 13,514 | 18,874 | 18,247 |
| EBIT 1 | 9,691 | 3,238 | -1,468 | 7,882 | 9,302 | 9,758 |
| Operating Margin | 8.23% | 2.04% | -0.88% | 4.17% | 2.37% | 2.14% |
| Earnings before Tax (EBT) 1 | 7,650 | 27,669 | -9,469 | 1,341 | 1,956 | 21,178 |
| Net income 1 | 5,135 | 22,147 | -8,737 | 1,392 | 721.3 | 17,907 |
| Net margin | 4.36% | 13.93% | -5.25% | 0.74% | 0.18% | 3.93% |
| EPS 2 | 148.0 | 1,103 | -452.0 | 72.53 | 37.57 | 557.0 |
| Free Cash Flow 1 | -11,412 | -1,667 | -13,253 | -14,604 | 9,029 | 201 |
| FCF margin | -9.69% | -1.05% | -7.96% | -7.72% | 2.3% | 0.04% |
| FCF Conversion (EBITDA) | - | - | - | - | 47.84% | 1.1% |
| FCF Conversion (Net income) | - | - | - | - | 1,251.79% | 1.12% |
| Dividend per Share | - | 63.00 | - | - | - | - |
| Announcement Date | 3/18/19 | 3/13/20 | 3/19/21 | 3/23/22 | 3/21/23 | 3/19/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 17,824 | - | 20,367 | 58,340 | 63,298 | 57,375 |
| Net Cash position 1 | - | 3,577 | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.464 x | - | 5.295 x | 4.317 x | 3.354 x | 3.144 x |
| Free Cash Flow 1 | -11,412 | -1,667 | -13,253 | -14,604 | 9,029 | 201 |
| ROE (net income / shareholders' equity) | 6.55% | 21.1% | -11.6% | 0.68% | -1.24% | 14.7% |
| ROA (Net income/ Total Assets) | 4.77% | 1.25% | -0.52% | 2.5% | 2.51% | 2.45% |
| Assets 1 | 107,729 | 1,778,010 | 1,675,630 | 55,696 | 28,725 | 730,036 |
| Book Value Per Share 2 | 4,029 | 5,270 | 5,041 | 5,162 | 5,038 | 5,547 |
| Cash Flow per Share 2 | 376.0 | 1,214 | 960.0 | 708.0 | 1,022 | 1,036 |
| Capex 1 | 3,339 | 6,348 | 8,362 | 5,223 | 4,359 | 3,113 |
| Capex / Sales | 2.84% | 3.99% | 5.02% | 2.76% | 1.11% | 0.68% |
| Announcement Date | 3/18/19 | 3/13/20 | 3/19/21 | 3/23/22 | 3/21/23 | 3/19/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +45.55% | 79.79M | |
| +21.55% | 72.37B | |
| +48.33% | 65.86B | |
| -4.21% | 34.41B | |
| -16.43% | 28.52B | |
| -7.17% | 14.26B | |
| -13.03% | 9.92B | |
| +5.83% | 9.52B | |
| +71.16% | 8.54B | |
| +26.49% | 8.36B |
- Stock Market
- Equities
- A038460 Stock
- Financials BioSmart Co.,Ltd.
